Mechanisms of Action of SGLT2 Inhibitors
SGLT2 inhibitors work primarily by blocking glucose reabsorption in the proximal renal tubules, causing glucosuria and lowering blood glucose through an insulin-independent mechanism. 1, 2
Primary Renal Mechanism
The core mechanism involves selective inhibition of SGLT2 proteins located in the S1 and S2 segments of the proximal convoluted tubule, where approximately 90% of filtered glucose is normally reabsorbed 2, 3, 2. By blocking this reabsorption, SGLT2 inhibitors:
- Increase urinary glucose excretion (glucosuria), with the amount excreted depending on both hyperglycemia level and glomerular filtration rate 1
- Lower the renal glucose threshold from approximately 180 mg/dL 4, 1
- Produce glucose-dependent effects that diminish as blood glucose normalizes, minimizing hypoglycemia risk 3
Secondary Metabolic Effects
Beyond glucose elimination, SGLT2 inhibitors improve glucose homeostasis through:
- Enhanced β-cell insulin secretion 1
- Improved peripheral insulin sensitivity 1
- These effects occur independently of β-cell function, allowing use regardless of diabetes duration (provided renal function is adequate) 1
Hemodynamic and Renal Protection Mechanisms
SGLT2 inhibitors produce natriuresis and osmotic diuresis without typically activating the renin-angiotensin-aldosterone system, likely through sympathetic inhibition via an incompletely understood pathway 1. Additional renal benefits include:
- Reduction of renal cortical hypoxia: By decreasing glucose reabsorption workload, proximal tubular cells consume less oxygen and ATP, improving tissue oxygenation 1
- Tubuloglomerular feedback modulation: Increased sodium delivery to the distal tubule causes afferent arteriole constriction, reducing intraglomerular pressure 2
- Structural kidney repair: Relief from excessive glucose reabsorption allows repair of interstitial tubular changes 1
Cardiovascular Mechanisms
The cardiac benefits extend beyond hemodynamic effects through:
- Direct myocardial effects: Reduction of fibrosis and inflammation with improved cardiac remodeling 1
- Indirect cardiovascular benefits: Volume overload improvement, blood pressure reduction (3-5 mmHg systolic), and improved renal hemodynamics 1, 4, 1
- Metabolic substrate shifts: Promotion of ketogenesis as an efficient energy source and upregulation of sirtuin 1 for stress resistance 5
Pleiotropic Cellular Mechanisms
Emerging evidence reveals additional cytoprotective pathways 5, 6:
- AMPK-mTORC1 signaling modulation: Attenuation of inflammation and oxidative stress
- Mitochondrial efficiency improvement: Enhanced cellular energy balance through substrate utilization shifts toward fatty acids and ketone bodies
- Anti-inflammatory effects: Reduction in systemic inflammation markers
- Erythropoiesis upregulation: Contributing to improved oxygen delivery
Clinical Implications of Mechanism
The insulin-independent mechanism allows SGLT2 inhibitors to be used:
- Without regard to diabetes duration (unlike agents requiring β-cell function) 1
- With minimal hypoglycemia risk when used alone 4, 3, 2
- In non-diabetic populations for heart failure and chronic kidney disease, as benefits extend beyond glycemic control 7, 8
Important Caveat on Renal Function
Efficacy declines with worsening renal function because the mechanism depends on glomerular filtration. Use with caution when GFR <45 mL/min/1.73 m² and adjust dosing per specific agent guidelines 1, 4, 1. The initial eGFR decline of approximately 5 mL/min (reaching nadir within 1-2 weeks) represents hemodynamic adjustment, not kidney injury, and typically returns toward baseline over 3-9 months 2.
Available Agents and Selectivity
Currently available SGLT2 inhibitors include dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, and sotagliflozin 1. Dapagliflozin, empagliflozin, and ertugliflozin are the most SGLT2-selective, while canagliflozin has greater SGLT1 inhibition (affecting intestinal glucose absorption) and sotagliflozin functions as a dual SGLT1/SGLT2 inhibitor 1.